Conference Coverage

Transgender youth on hormone therapy risk substantial bone loss


 

FROM ENDO 2022

Monitor bone in transgender youth; Use vitamin D and weight-bearing exercise

Dr. O’Connell is the first author of a recent summary of the pharmacologic management of trans and gender-diverse adolescents. That summary covered multiple topics in addition to risk of bone loss, including the impact on growth, cognition, and mental health (J Clin Endocrinol Metab. 2022 Jan;107:241-257).

Overall, she believes that bone health should be monitored for children receiving puberty-delaying or gender-affirming therapies but agrees with Dr. Nokoff that the clinical impact remains poorly defined.

“Long-term follow-up studies will be required to assess the impact, if any, on functional outcomes such as fracture risk,” she reported. Still, she encouraged use of standard ways of improving bone health, including adequate vitamin D intake and weight-bearing exercise.

Dr. Nokoff and Dr. O’Connell have disclosed no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Risk for severe COVID-19 and death plummets with Pfizer booster
MDedge Internal Medicine
WPATH draft on gender dysphoria ‘skewed and misses urgent issues’
MDedge Internal Medicine
Proposed insurance policy ignites debate over transgender health care
MDedge Internal Medicine
Doctors have failed them, say those with transgender regret
MDedge Internal Medicine
Breast anatomy and augmentation in transfeminine individuals
MDedge Internal Medicine
Trans women in female sports: A sports scientist’s take
MDedge Internal Medicine
New studies show growing number of trans, nonbinary youth in U.S.
MDedge Internal Medicine
Biden boosts LGBTQIA+ protections, bans conversion therapy
MDedge Internal Medicine
LGBTQ students would get new protections under Biden plan
MDedge Internal Medicine
Alabama cites Roe decision in call to ban transgender health care
MDedge Internal Medicine